MNKD
Price
$3.02
Change
-$0.03 (-0.98%)
Updated
Oct 14, 04:59 PM (EDT)
Capitalization
1.08B
27 days until earnings call
Intraday BUY SELL Signals
UTHR
Price
$545.11
Change
+$1.70 (+0.31%)
Updated
Oct 14, 11:22 AM (EDT)
Capitalization
20.83B
21 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

MNKD vs UTHR

MNKD vs UTHR Comparison Chart in %
loading
loading
View a ticker or compare two or three
VS
MNKD vs. UTHR commentary
Oct 14, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is MNKD is a Hold and UTHR is a Hold.

Interact to see
Advertisement
SUMMARIES
A.I.Advisor
a Summary for MNKD with price predictions
Oct 13, 2026

MNKD in downward trend: 10-day moving average crossed below 50-day moving average on September 09, 2026

The 10-day moving average for MNKD crossed bearishly below the 50-day moving average on September 09, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 11 of 13 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 85%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on October 09, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on MNKD as a result. In 78 of 93 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 84%.

The Moving Average Convergence Divergence Histogram (MACD) for MNKD turned negative on October 09, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 48 similar instances when the indicator turned negative. In 40 of the 48 cases the stock turned lower in the days that followed. This puts the odds of success at 83%.

MNKD moved below its 50-day moving average on October 02, 2026 date and that indicates a change from an upward trend to a downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where MNKD declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 79%.

MNKD broke above its upper Bollinger Band on September 30, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

The Aroon Indicator for MNKD entered a downward trend on September 24, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Bullish Trend Analysis

The RSI Indicator demonstrates that the ticker has stayed in the oversold zone for 1 day, which means it's wise to expect a price bounce in the near future.

The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 2 days, which means it's wise to expect a price bounce in the near future.

Following a +18.26% 3-day Advance, the price is estimated to grow further. Considering data from situations where MNKD advanced for three days, in 206 of 258 cases, the price rose further within the following month. The odds of a continued upward trend are 80%.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 5 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is 63 (best 1 - 100 worst), indicating steady price growth. MNKD’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of 92 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (-6.392) is normal, around the industry mean (26.782). P/E Ratio (143.000) is within average values for comparable stocks, (43.395). Projected Growth (PEG Ratio) (0.220) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (0.000) among similar stocks. P/S Ratio (2.832) is also within normal values, averaging (437.542).

The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. MNKD’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

A.I.Advisor
a Summary for UTHR with price predictions
Oct 13, 2026

UTHR in upward trend: 10-day moving average moved above 50-day moving average on October 06, 2026

The 10-day moving average for UTHR crossed bullishly above the 50-day moving average on October 06, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 11 of 14 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 79%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on September 30, 2026. You may want to consider a long position or call options on UTHR as a result. In 58 of 94 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 62%.

The Moving Average Convergence Divergence (MACD) for UTHR just turned positive on September 30, 2026. Looking at past instances where UTHR's MACD turned positive, the stock continued to rise in 33 of 50 cases over the following month. The odds of a continued upward trend are 66%.

UTHR moved above its 50-day moving average on September 30, 2026 date and that indicates a change from a downward trend to an upward trend.

Following a +3.25% 3-day Advance, the price is estimated to grow further. Considering data from situations where UTHR advanced for three days, in 221 of 314 cases, the price rose further within the following month. The odds of a continued upward trend are 70%.

Bearish Trend Analysis

The 10-day RSI Indicator for UTHR moved out of overbought territory on October 02, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 39 similar instances where the indicator moved out of overbought territory. In 20 of the 39 cases, the stock moved lower in the following days. This puts the odds of a move lower at 51%.

The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 43 of 65 cases where UTHR's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 66%.

The 50-day moving average for UTHR moved below the 200-day moving average on September 10, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where UTHR declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 59%.

UTHR broke above its upper Bollinger Band on September 30, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

The Aroon Indicator for UTHR entered a downward trend on September 29, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Profit vs. Risk Rating rating for this company is 14 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 84, placing this stock better than average.

The Tickeron PE Growth Rating for this company is 32 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is 43 (best 1 - 100 worst), indicating steady price growth. UTHR’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 48 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Valuation Rating of 76 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.254) is normal, around the industry mean (43.873). P/E Ratio (17.397) is within average values for comparable stocks, (141.710). Projected Growth (PEG Ratio) (2.205) is also within normal values, averaging (2.152). Dividend Yield (0.000) settles around the average of (0.005) among similar stocks. P/S Ratio (7.418) is also within normal values, averaging (178.797).

The Tickeron Seasonality Score of 85 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

FUNDAMENTALS RATINGS
MNKD vs UTHR: Fundamental Ratings
MNKD
UTHR
OUTLOOK RATING
1..100
6230
VALUATION
overvalued / fair valued / undervalued
1..100
92
Overvalued
76
Overvalued
PROFIT vs RISK RATING
1..100
10014
SMR RATING
1..100
10048
PRICE GROWTH RATING
1..100
6343
P/E GROWTH RATING
1..100
532
SEASONALITY SCORE
1..100
n/a85

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

UTHR's Valuation (76) in the Pharmaceuticals Other industry is in the same range as MNKD (92) in the Biotechnology industry. This means that UTHR’s stock grew similarly to MNKD’s over the last 12 months.

UTHR's Profit vs Risk Rating (14) in the Pharmaceuticals Other industry is significantly better than the same rating for MNKD (100) in the Biotechnology industry. This means that UTHR’s stock grew significantly faster than MNKD’s over the last 12 months.

UTHR's SMR Rating (48) in the Pharmaceuticals Other industry is somewhat better than the same rating for MNKD (100) in the Biotechnology industry. This means that UTHR’s stock grew somewhat faster than MNKD’s over the last 12 months.

UTHR's Price Growth Rating (43) in the Pharmaceuticals Other industry is in the same range as MNKD (63) in the Biotechnology industry. This means that UTHR’s stock grew similarly to MNKD’s over the last 12 months.

MNKD's P/E Growth Rating (5) in the Biotechnology industry is in the same range as UTHR (32) in the Pharmaceuticals Other industry. This means that MNKD’s stock grew similarly to UTHR’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
MNKDUTHR
RSI
ODDS (%)
Bullish Trend 2 days ago
90%
Bearish Trend 2 days ago
51%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
78%
Bearish Trend 2 days ago
66%
Momentum
ODDS (%)
Bearish Trend 2 days ago
84%
Bullish Trend 2 days ago
62%
MACD
ODDS (%)
Bearish Trend 2 days ago
83%
Bullish Trend 2 days ago
66%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
79%
Bullish Trend 2 days ago
67%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
77%
Bullish Trend 2 days ago
69%
Advances
ODDS (%)
Bullish Trend 14 days ago
80%
Bullish Trend 3 days ago
70%
Declines
ODDS (%)
Bearish Trend 2 days ago
79%
Bearish Trend 10 days ago
59%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
75%
Bearish Trend 2 days ago
61%
Aroon
ODDS (%)
Bearish Trend 2 days ago
73%
Bearish Trend 2 days ago
66%
COMPARISON
Comparison
Oct 14, 2026
Stock price -- (MNKD: $3.05 vs. UTHR: $543.40)
Brand notoriety: MNKD and UTHR are both not notable
MNKD represents the Biotechnology, while UTHR is part of the Pharmaceuticals: Generic industry
Current volume relative to the 65-day Moving Average: MNKD: 112% vs. UTHR: 100%
Market capitalization -- MNKD: $1.08B vs. UTHR: $20.83B
MNKD [@Biotechnology] is valued at $1.08B. UTHR’s [@Pharmaceuticals: Generic] market capitalization is $20.83B. The market cap for tickers in the [@Biotechnology] industry ranges from $58 to $133.74B. The market cap for tickers in the [@Pharmaceuticals: Generic] industry ranges from $2.12K to $68.49B. The average market capitalization across the [@Biotechnology] industry is $2.21B. The average market capitalization across the [@Pharmaceuticals: Generic] industry is $4.13B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

MNKD’s FA Score shows that 1 FA rating(s) are green while UTHR’s FA Score has 2 green FA rating(s).

  • MNKD’s FA Score: 1 green, 4 red.
  • UTHR’s FA Score: 2 green, 3 red.
According to our system of comparison, UTHR is a better buy in the long-term than MNKD.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

MNKD’s TA Score shows that 3 TA indicator(s) are bullish while UTHR’s TA Score has 5 bullish TA indicator(s).

  • MNKD’s TA Score: 3 bullish, 7 bearish.
  • UTHR’s TA Score: 5 bullish, 6 bearish.
According to our system of comparison, UTHR is a better buy in the short-term than MNKD.

Price Growth

MNKD (@Biotechnology) experienced а -17.79% price change this week, while UTHR (@Pharmaceuticals: Generic) price change was +0.33% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -7.22%. For the same industry, the average monthly price growth was -17.98%, and the average quarterly price growth was -18.86%.

The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was -5.16%. For the same industry, the average monthly price growth was -5.18%, and the average quarterly price growth was +11.32%.

Reported Earning Dates

MNKD is expected to report earnings on Nov 10, 2026.

UTHR is expected to report earnings on Nov 04, 2026.

Industries' Descriptions

@Biotechnology (-7.22% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

@Pharmaceuticals: Generic (-5.16% weekly)

A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.

View a ticker or compare two or three
MNKD
Daily Signal:
Gain/Loss:
UTHR
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
CMT23.690.22
+0.94%
Core Molding Technologies
STLD240.631.49
+0.62%
Steel Dynamics
BRBR8.51-0.08
-0.93%
BellRing Brands
TNGX22.22-1.95
-8.07%
Tango Therapeutics
PASG3.64-0.91
-20.00%
Passage Bio Inc

MNKD and

Correlation & Price change

A.I.dvisor indicates that over the last year, MNKD has been loosely correlated with VCYT. These tickers have moved in lockstep 44% of the time. This A.I.-generated data suggests there is some statistical probability that if MNKD jumps, then VCYT could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To MNKD
1D Price
Change %
MNKD100%
-2.56%
VCYT - MNKD
44%
Loosely correlated
-2.07%
UTHR - MNKD
37%
Loosely correlated
-1.22%
AMRN - MNKD
36%
Loosely correlated
+0.43%
AXON - MNKD
35%
Loosely correlated
-0.26%
VIR - MNKD
32%
Poorly correlated
-6.11%
More

UTHR and

Correlation & Price change

A.I.dvisor indicates that over the last year, UTHR has been loosely correlated with MNKD. These tickers have moved in lockstep 38% of the time. This A.I.-generated data suggests there is some statistical probability that if UTHR jumps, then MNKD could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To UTHR
1D Price
Change %
UTHR100%
-1.22%
MNKD - UTHR
38%
Loosely correlated
-2.56%
GERN - UTHR
37%
Loosely correlated
-1.64%
ALNY - UTHR
36%
Loosely correlated
-1.41%
CBIO - UTHR
36%
Loosely correlated
-10.72%
INSM - UTHR
35%
Loosely correlated
-1.80%
More